安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Our Science - Sana Biotechnology
Sana’s in vivo Cell Engineering platform aims to provide solutions for patients that current gene therapies cannot address Success will require creative science, experienced product and clinical development strategies, and aggregating important technologies
- Home - Sana Biotechnology
Sana is creating engineered cells to repair and control genes in cells or replace missing or damaged cells to solve the underlying causes of disease
- Our Pipeline - Sana Biotechnology
Sana is committed to developing safe and effective engineered cells as medicines, which involves evaluation in clinical trials followed by submission of the trial results to regulatory agencies, such as the U S Food and Drug Administration (FDA)
- For Patients - Sana Biotechnology
Sana is a science-driven, patient-centric company filled with employees who wake up everyday focused on advancing potentially curative medicines for people in need
- Our Story - Sana Biotechnology
Sana was founded with the long view – bringing together great people and the best technologies to deliver on the challenging promise of engineered cells as medicines Three aspirations drive Sana as we look to treat patients with poor outcomes or currently untreatable diseases
- Investor Relations | Sana Biotechnology, Inc
Sana Biotechnology, Inc is focused on creating and delivering engineered cells as medicines for patients We share a vision of repairing and controlling genes, replacing missing or damaged cells, and making our therapies broadly available to patients
- News - Sana Biotechnology
Explore news and announcements from Sana Biotechnology to learn more about progress in engineering cells to be medicines
- Gary Meininger, MD - Sana Biotechnology
Gary Meininger, MD, is Executive Vice President and Chief Medical Officer at Sana Biotechnology Prior to joining Sana, Gary served as Senior Vice President and Head of Clinical Development at Vertex Cell and Genetic Therapies (VCGT), where he oversaw all aspects of clinical development for VCGT disease areas, including sickle cell disease
|
|
|